623. Mantle Cell, Follicular, Waldenstrom's, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III

Promote FL Pirtobrutinib and mosunetuzumab to enhance treatment efficacy for patients with relapsed refractory follicular lymphoma

EPCORE FL 2 Phase 3 trial of epcoritamab with rituximab and lenalidomide R2 vs chemoimmunotherapy CIT in previously untreated follicular lymphoma FL Trial in progress

Mass spectrometry demonstrates very frequent multi clonality in familial Waldenstroem macroglobulinemia and shows distinct IgM profiles across IgM related disorders

Validation of baseline total metabolic tumor volume TMTV as a predictor of early progression POD24 in follicular lymphoma A retrospective study of 100 patients in Brazil

Determining the origin of TP53 mutations in patients with mature B cell neoplasms is essential to distinguish lymphoma related mutations from those due to clonal hematopoiesis helping to guide treatment decisions

Risk of lymphoma with antimetabolite and biologic combinations A pharmacovigilance analysis using the FDA adverse event reporting system database

Pooled analysis of early Phase trials highlights robust activity of CD3 CD20 T cell engagers in follicular lymphoma

Is functional cure possible in follicular lymphoma analysis and development of a predictive model for long term progression free PFS15 patients

Evaluating the clinical outcomes of GLP 1 receptor agonists in untreated indolent non Hodgkin s lymphomas undergoing active surveillance

Efficacy and safety of zanubrutinib plus bendamustine rituximab in newly diagnosed Mantle Cell Lymphoma with TP53 abnormalities or chemotherapy intolerance

Odronextamab Odro plus lenalidomide Len in patients with relapsed refractory R R follicular lymphoma FL First results from part 1 safety lead in of the Phase 3 OLYMPIA 5 study

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma Orion Study

EO2463 EO peptide immunotherapy in patients pts with newly diagnosed asymptomatic follicular lymphoma FL and marginal zone lymphoma MZL Study EONHL1 20 sidney NCT04669171 primary endpoint lugano objective response analysis

Analysis of the role of baseline PET CT in a prospective study of unselected patients The UK MCL biobank

Phase II investigator initiated trial of epcoritamab lenalidomide in treatment naïve follicular lymphoma

Phase 1 study of MK 1045 a novel CD19xCD3 T cell engager in participants with relapsed or refractory follicular lymphoma

Time stratified risk of second primary solid malignancies among follicular lymphoma survivors in the United States

Health related quality of life HRQoL in patients with relapsed refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide E R2 Primary results of the EPCORE FL 1 trial

Preliminary results of a first in human Phase 1 study of GLB 002 a novel molecular glue degrader of IKZF1 3 in patients with relapsed or refractory non Hodgkin lymphoma

Phase 3 study inMIND of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma Clinical characteristics and outcomes of high risk patients

Final efficacy results of the real life ambispective urban study on frontline obinutuzumab based immunochemotherapy for advanced follicular lymphoma

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed refractory mantle cell lymphoma

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients Long term results of the FIL FLAZ12 Phase III randomized trial

A comprehensive geriatric assessment to evaluate individual frailty status and quality of life in patients with Waldenstroem macroglobulinemia A prospective italian study

Prognostic value of combining beta 2 microglobulin and total metabolic tumor volume in patients with follicular lymphoma A post hoc analysis of the relevance trial

Safety and efficacy of zanubrutinib in waldenstrom macroglobulinemia patients treated in common clinical practice A retrospective prospective study by fondazione italiana linfomi FIL

Phase I ? study evaluating the safety and preliminary efficacy of amulirafusp alfa IMM0306 in combination with lenalidomide in patients with relapsed refractory CD20 positive follicular lymphoma

Fixed duration epcoritamab in combination with bendamustine Rituximab BR for first line 1L treatment of follicular lymphoma FL 3 year results from EPCORE NHL 2 arm 3 demonstrate deep and durable responses with manageable safety

Real world effectiveness and safety outcomes by age comorbidity frailty and treatments prior to infusion in relapsed or refractory R R follicular lymphoma patients treated with axicabtagene ciloleucel

Long term safety and long term disease control of oral ixazomib and short course rituximab in untreated iNHL

FLP R A clinical prediction model for follicular lymphoma Prognosis in the Relapsed refractory setting

Fixed duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed refractory follicular lymphoma after =2 prior therapies 3 year follow up from a pivotal Phase II study

Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed refractory R R follicular lymphoma FL after =2 prior therapies 5 year follow up of a pivotal Phase II study

Multi center real world analysis of treatment outcomes of non COVALENT btki pirtobrutinib in patients with COVALENT btki relapsed refracdtory Mantle Cell Lymphoma

Spanish real life practice confirms zanubrutinib as a safe and effective option in relapsed or refractory marginal zone lymphoma Results of a cohort of 118 patients on behalf of GELTAMO

Promising efficacy of BI 1206 an antibody targeting Fc?RIIB in combination with rituximab and acalabrutinib in R R NHL patients NHL

Evaluation of PET CT during upfront therapy as a prognosticator in follicular lymphoma patients at the University of Debrecen